The Food and Drug Administration yesterday released a blueprint for educating health care providers that treat or monitor patients with pain under its forthcoming Risk Evaluation and Mitigation Strategy for companies that make opioid pain relievers. Accredited continuing education providers will use the blueprint to develop educational materials and activities for the REMS. FDA Commissioner Scott Gottlieb, M.D., said the revised blueprint includes more information on pain management and pharmacologic treatments for pain, including non-opioid pain relievers. In other news, FDA said it is working with manufacturers on safer packaging for Imodium A-D (loperamide) because some people addicted to opioids are taking the over-the-counter anti-diarrhea drug at dangerously high doses to manage withdrawal or achieve euphoric effects. Taking more than prescribed or listed on the label can cause severe heart rhythm problems or death.

Related News Articles

Headline
Continued rising drug prices, as well as shortages for many critical medications, are disrupting patient care and forcing hospitals to delay infrastructure and…
Headline
U.S. overdose death rates linked to synthetic opioids increased more than 45 percent in 2017, likely driven by illicitly manufactured fentanyl, according to a…
Headline
The Health Resources and Services Administration recently launched a program to provide eligible health care clinicians with student loan repayment assistance…
Insights and Analysis
Also in this weekly roundup of health care news: how mandated access to at-home palliative care has made all the difference for some patients; and a town’s…
Headline
Clinicians should strongly consider prescribing or co-prescribing naloxone to certain patients at risk for opioid overdose, and educating them about its use,…
Headline
The Food and Drug Administration yesterday approved a mobile medical application to help increase retention in outpatient treatment programs for opioid use…